en · de · es · fr · pt
analytical-notes.peptides6823.com › News › Handling, Stability And Analysis — Research Overview

Handling, Stability And Analysis — Research Overview

By Editorial Desk · published 2026-07-09 · last reviewed 2026-08-01 · News

Everything below concerns DAC linker. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

CJC-1295 Background and Mechanism

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Cjc-1295 at a glance

PropertyValueNotes
Appearance as powderWhite to off-white solidMinor batch-to-batch variation is normal
Solubility classSoluble in water and aqueous buffersDissolution can be slowed by aggregates
Typical storage temperatureMinus 20 degrees Celsius or belowProtected from light and moisture
Storage after reconstitution2 to 8 degrees Celsius, short termLonger holding requires freezing
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity and identity confirmation

Structure And Receptor Pharmacology

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

Related pages on this site

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Notes from published material

== Occurrence == Seeds and phytopharmaceuticals derived from the plant Ginkgo biloba are dietary supplements used to improve memory, brain metabolism, and blood flow, and to treat neuronal disorders. It has been long used for a wide range of medicinal purposes. For instance, in Japan and China, Ginkgo biloba is used to treat cough, bronchial asthma, irritable bladder and alcohol use disorder. Ginkgotoxin is found in the seeds and, in lesser amounts, in the leaves of Ginkgo biloba. The seeds can be consumed as is and the leaves can be used to prepare the dietary supplements. Analyses of raw seeds from eight different locations in Japan by high-performance liquid chromatography showed concentrations of ginkgotoxin varying from 0.173 to 0.4 mg/g of seeds. Also, there is a seasonal variation of ginkgotoxin concentration in the seeds. The maximum has been observed in August. Analyses of the powder of Ginkgo biloba capsules revealed the presence of ginkgotoxin. However, as most oral supplements are made from the leaves, which contain only small amounts of ginkgotoxin, below the level of toxicological relevance. Ginkgotoxin-5'-glucoside is a derivative of ginkgotoxin that possesses a glycosyl in the 5' position. Its content is higher than the concentration of ginkgotoxin in heated seeds (boiled or roasted). Liberation of ginkgotoxin by enzymatic hydrolysis of the glycosidic linkage is possible. Nevertheless, the toxicity or the mechanism of action of the glucoside form is not fully understood. Ginkgotoxin can also be found in plants of the genus Albizia.

After graduating, she accepted a postdoctoral fellowship at the Scripps Research Institute in La Jolla, California, where she worked under the guidance of Dr. Eric F. Johnson to study the regulation of CYP4A and CYP4F genes in mice. She studied what cellular pathways regulated fatty acid metabolism and how stress pathways influence the CYPs that metabolize lipids.

== Structural studies == As of late 2007, 8 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1VKN​, PDB: 2CVO​, PDB: 2G17​, PDB: 2I3A​, PDB: 2I3G​, PDB: 2NQT​, PDB: 2OZP​, and PDB: 2Q49​.

Gearbox Software was founded on February 16, 1999, by Randy Pitchford, Brian Martel, Stephen Bahl, Landon Montgomery and Rob Heironimus, five developers formerly of Rebel Boat Rocker. Before Rebel Boat Rocker, Pitchford and Martel previously worked together at 3D Realms, and Montgomery previously worked at Bethesda Softworks. By 2000, the company employed 15 people. They started with developing expansions to Valve's Half-Life. Porting Half-Life to console platforms (each with new game content) followed, building the company's experience in console game-making, in addition to enhancing and building upon the successful Counter-Strike branch of the Half-Life franchise. Prior to Half-Life 2, it had developed or helped develop every Half-Life expansion game or port, including Opposing Force, Blue Shift, Counter-Strike: Condition Zero, Half-Life for the Sony PlayStation 2 (including Half-Life: Decay), and Half-Life for the Sega Dreamcast (including Blue Shift). Branching out to other publishers, it pursued additional port work, each game being released with additional content, but this time from console to PC. These projects included its first non-first-person shooter, Tony Hawk's Pro Skater 3, and Halo: Combat Evolved, forging new publisher relationships with Activision and Microsoft Game Studios respectively. Additional new development, in the form of a PC game in the James Bond franchise (James Bond 007: Nightfire) for Electronic Arts, also occurred during the company's initial 5-year period.

=== European Union === The European Union-funded project SYNBIOSAFE has issued reports on how to manage synthetic biology. A 2007 paper identified key issues in safety, security, ethics, and the science-society interface, which the project defined as public education and ongoing dialogue among scientists, businesses, government and ethicists. The key security issues that SYNBIOSAFE identified involved engaging companies that sell synthetic DNA and the biohacking community of amateur biologists. Key ethical issues concerned the creation of new life forms. A subsequent report focused on biosecurity, especially the so-called dual-use challenge. For example, while synthetic biology may lead to more efficient production of medical treatments, it may also lead to synthesis or modification of harmful pathogens (e.g., smallpox). The biohacking community remains a source of special concern, as the distributed and diffuse nature of open-source biotechnology makes it difficult to track, regulate or mitigate potential concerns over biosafety and biosecurity. COSY, another European initiative, focuses on public perception and communication. To better communicate synthetic biology and its societal ramifications to a broader public, COSY and SYNBIOSAFE published SYNBIOSAFE, a 38-minute documentary film, in October 2009. The International Association Synthetic Biology has proposed self-regulation. This proposes specific measures that the synthetic biology industry, especially DNA synthesis companies, should implement.

Sources: en.wikipedia.org

Background from the literature

Many of the essential molecules for life on Earth can exist in two mirror-image forms, often called "left-handed" and "right-handed", but living organisms do not use both. (Handedness refers to the direction in which polarized light skews when beamed through a pure solution of the molecule.) RNA and DNA contain only right-handed sugars; proteins made by the ribosome are exclusively composed of left-handed amino acids. This phenomenon is known as homochirality. It is not known whether homochirality emerged before or after life, whether the building blocks of life must have this particular chirality, or indeed whether life needs to be homochiral. Protein chains built from amino acids of mixed chirality tend not to fold or function well, but mirror-image proteins have been constructed that have identical function but on substrates of opposite handedness.

=== Powerplant === Four Kuznetsov NK-86 two-spool with five-stage LP compressors, six-stage HP compressors, annular combustor cans, single-stage HP turbine and two-stage LP turbine turbofan engines power the Il-86. The cascade thrust reversers are canted 15° in respect to the horizontal axis. Pneumatic starters start the engines (airborne relights use the windmill effect). The forward-facing ejectors blow away detritus during taxi. International Standard Atmosphere hourly fuel consumption per engine is 7.7 t (16,975 lb) at maximum continuous rated thrust, 6 t/13,230 lb at nominal maximum thrust, 5.1 t (11,243 lb) at 85% thrust, 4.2 t/9260 lb at 70%, 3.6 t (7,937 lb) at 60%, 2.45 t (5,400 lb) at 40% and 1 t (2,205 lb) at idle. Overall hourly fuel consumption at long-range cruise and 190 t (419,000 lb) is 9.75 t (21,495 lb) reducing to 7.79 t (17,174 lb) at 140 t (308,650 lb). Outboard engine pylons on the latter two-thirds of all Il-86s are marginally extended to cut drag. The VSU-10 APU generates power and heats/cools the interior on the ground, and provides engine start air.

==== Education and intelligence ==== Research suggests neither a good education nor a high IQ reliably increases happiness. Anders Ericsson argued an IQ above 120 has a decreasing influence on success. Presumably, IQs above 120 do not additionally cause other happiness indicators like success (with the exception of careers like Theoretical physics, where high IQs are more predictive of success). Above that IQ level, other factors, like social skills and a good mentor, matter more. As these relate to happiness, intelligence and education may simply allow one to reach a middle-class level of need satisfaction (as mentioned above, being richer than this seems to hardly affect happiness). According to the findings of the study, Using Theatrical Concepts for Role-plays with Educational Agents by Klesen, she expresses how role- playing embeds information and educational goals and causes people to learn unintentionally. Studies have shown that enjoyment in things as simple as role playing increases a person's IQ and their happiness. Martin Seligman has said: "As a professor, I don't like this, but the cerebral virtues—curiosity, love of learning—are less strongly tied to happiness than interpersonal virtues like kindness, gratitude and capacity for love."

NAD(P)H dehydrogenase [quinone] 1 is an enzyme that in humans is encoded by the NQO1 gene. This protein-coding gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a 2-electron reductase (enzyme). This FAD-binding protein forms homodimers and performs two-electron reduction of quinones to hydroquinones and of other redox dyes. It has a preference for short-chain acceptor quinones, such as ubiquinone, benzoquinone, juglone and duroquinone. This gene has an important paralog NQO2. This protein is located in the cytosol. NQO1 enzyme expression can be induced by dioxin and inhibited by dicoumarol.

Sources: en.wikipedia.org

Further detail

=== Miscellaneous === Galactogogues such as the peripherally selective D2 receptor antagonist and prolactin releaser domperidone can be used to induce lactation in transgender women who wish to breastfeed. An extended period of combined estrogen and progestogen therapy is necessary to mature the lobuloalveolar tissue of the breasts before this can be successful. There are several published reports of lactation and/or breastfeeding in transgender women. The World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8), released in September 2022, recommends against therapeutic strategies including supraphysiological estradiol levels (>200 pg/mL), use of progesterone (including rectal progesterone), use of bicalutamide, and monitoring of the ratio of estrone to estradiol. This is due to lack of data to support these approaches in transfeminine people as well as potential risks. The WPATH SOC8 also recommends against the use of 5α-reductase inhibitors such as finasteride in transfeminine people.

Fracture mechanics is the field of mechanics concerned with the study of the propagation of cracks in materials. It uses methods of analytical solid mechanics to calculate the driving force on a crack and those of experimental solid mechanics to characterize the material's resistance to fracture. Theoretically, the stress ahead of a sharp crack tip becomes infinite and cannot be used to describe the state around a crack. Fracture mechanics is used to characterise the loads on a crack, typically using a single parameter to describe the complete loading state at the crack tip. A number of different parameters have been developed. When the plastic zone at the tip of the crack is small relative to the crack length the stress state at the crack tip is the result of elastic forces within the material and is termed linear elastic fracture mechanics (LEFM) and can be characterised using the stress intensity factor

A history of widespread pain lasting more than three months – affecting all four quadrants of the body, i.e., both sides and above and below the waist. Tender points – there are 18 designated possible tender points (although a person with the disorder may feel pain in other areas as well). The ACR criteria for the classification of patients were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis, but have later become the de facto diagnostic criteria in the clinical setting. A controversial study was done by a legal team looking to prove their client's disability based primarily on tender points, and their widespread presence in non-litigious communities prompted the lead author of the ACR criteria to question the usefulness of tender points in diagnosis. Use of control points has been used to cast doubt on whether a person has fibromyalgia, and to claim the person is malingering. In 2010, the American College of Rheumatology approved provisional revised diagnostic criteria for fibromyalgia that eliminated the 1990 criteria's reliance on tender point testing. The revised criteria used a widespread pain index (WPI) and symptom severity scale (SSS) in place of tender point testing under the 1990 criteria. The WPI counts up to 19 general body areas in which the person has experienced pain in the preceding week. The SSS rates the severity of the person's fatigue, unrefreshed waking, cognitive symptoms, and general somatic symptoms, each on a scale from 0 to 3, for a composite score ranging from 0 to 12.

Sources: en.wikipedia.org

Frequently asked questions

Why is mass spectrometry used alongside chromatography?

Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.

What drives degradation of the peptide in solution?

Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.

Is a purity percentage directly comparable between suppliers?

Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Network